Breast Cancer Index-test

The Predictive Power Of Breast Cancer Index^®

Breast Cancer Index Has Demonstrated Consistent Predictive Evidence Across 5 Studies and Over 4,500 Patients^1-5

Data supports comprehensive utility in pre- and post-menopausal women with various treatment histories and clinical features

Studies included patients with node-positive and node-negative disease, encompassing tumor sizes T1-3 and grades 1-3.

^†For patients disease-free at year 5

The HOXB13/IL17BR (BCI) ratio remains the only biomarker that has demonstrated significant treatment interaction for prediction of extended endocrine therapy benefit, earning guideline inclusion earlier this year.”

— Mark Pegram, MD

Read the Full Breast Cancer Index Predictive Validation Studies

1. Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence »

2. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker »

3. Breast Cancer Index and Prediction of Benefit From Extended Endocrine Therapy in Breast Cancer Patients Treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) Trial »

4. Breast Cancer Index predicts extended endocrine benefit to individualize selection of HR+ early stage breast cancer patients for 10 years of endocrine therapy »

5. Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42 »

References: 1. Zhang Y, et al. Clin Cancer Res. 2013;19(15):4196-4205. 2. Sgroi DC, et al. J Natl Cancer Inst. 2013;105(14):1036-1042. 3. Bartlett JMS, et al. Ann Oncol. 2019;300(11):1776-1783. 4. Noordhoek I, et al. Clin Cancer Res. 2021;27(1):311-319. 5. Mamounas EP, et al. Abstract 501; ASCO^® Clinical Practice Guideline June 2021. 6. Simon RM, et al. J Natl Cancer Inst. 2009;101(21):1446-1452.

Back To All

The Predictive Power Of Breast Cancer Index®

Breast Cancer Index Has Demonstrated Consistent Predictive Evidence Across 5 Studies and Over 4,500 Patients1-5

The HOXB13/IL17BR (BCI) ratio remains the only biomarker that has demonstrated significant treatment interaction for prediction of extended endocrine therapy benefit, earning guideline inclusion earlier this year.” — Mark Pegram, MD

Read the Full Breast Cancer Index Predictive Validation Studies

The Predictive Power Of Breast Cancer Index^®

Breast Cancer Index Has Demonstrated Consistent Predictive Evidence Across 5 Studies and Over 4,500 Patients^1-5

The HOXB13/IL17BR (BCI) ratio remains the only biomarker that has demonstrated significant treatment interaction for prediction of extended endocrine therapy benefit, earning guideline inclusion earlier this year.”

— Mark Pegram, MD